TAK | tickerfilter.com

Fundamental analysis

17%

Profitability 18%

Dept financing 15%

Liquidity 40%

Performance 11%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.19%

1 Month

2.36%

3 Months

28.49%

6 Months

18.31%

1 Year

21.14%

2 Year

26.53%

Key data

Stock price

$18.22

P/E Ratio

51.15

DAY RANGE

$18.08 - $18.26

EPS

$0.29

52 WEEK RANGE

$12.99 - $18.82

52 WEEK CHANGE

$21.47

MARKET CAP

47.378 B

YIELD

4.06%

SHARES OUTSTANDING

3.182 B

DIVIDEND

$0.2922

EX-DIVIDEND DATE

03-27-2024

NEXT EARNINGS DATE

07-30-2025

BETA

0.15

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,683,256

AVERAGE 30 VOLUME

$2,719,510

Company detail

CEO: Christophe Weber
Region: US
Website: takeda.com
Employees: 47,300
IPO year: 2008

Issue type: American Depository Receipt (ADR’s)
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in gastroenterology; oncology; neuroscience; and rare diseases. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig.

TAK - TAKEDA PHARMACEUTICAL CO LTD